In a noteworthy development, Goldman Sachs has initiated coverage on Syndax Pharmaceuticals (SNDX, Financial) with a "Buy" rating. The announcement, made by analyst Corinne Johnson, highlights the investment firm's positive outlook on the pharmaceutical company.
Goldman Sachs has set a price target of USD 18.00 for SNDX, which is notable as it indicates a potential upside in the stock's performance. This target reflects the investment bank's confidence in the future prospects of Syndax Pharmaceuticals.
This coverage initiation by Goldman Sachs marks a significant step for SNDX, as it enters the spotlight with a strong endorsement from a leading financial analyst. Investors in Syndax Pharmaceuticals will be closely monitoring any developments following this coverage initiation on July 10, 2025.
The "Buy" rating from Goldman Sachs positions SNDX as a stock to watch in the pharmaceutical sector. With no prior ratings, this coverage initiation sets a new benchmark for the company's future performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for Syndax Pharmaceuticals Inc (SNDX, Financial) is $33.83 with a high estimate of $51.00 and a low estimate of $17.00. The average target implies an upside of 266.16% from the current price of $9.24. More detailed estimate data can be found on the Syndax Pharmaceuticals Inc (SNDX) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, Syndax Pharmaceuticals Inc's (SNDX, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
